Table 1. Comparative safety estimates
| Safety Issue | Estimated Risk Difference |
|---|---|
| SIs in RA | 1–2 fewer SIs/100-pts treated with ETN for 3–12 months vs ADA and IFXa |
| 1–2 fewer SIs/100-pts treated with ADA, ETN, GLM and IFX for 6 months vs CZPb | |
| TB | 1 less case/1000 pt-yrs treated with ETN vs ADA and IFXa |
| Non-TB OIs | 1 less case/1000 pt-yrs treated with ETN vs ADA and IFXb |
| Lymphoma | 1 less case/1000 pt-yrs treated with ETN vs ADA and IFXb |
| Withdrawals and withdrawals due to adverse events in RAc | 2 fewer withdrawals/100-pts per year with ETN vs ADAa |
| 6 fewer withdrawals/100-pts per year with ETN vs IFXa |
aBorderline: evidence may be reliable enough to inform decisions but caution is urged and further evidence is needed. bInconclusive: evidence may be absent, conflicting, sparse, or weak and evidence-based conclusions cannot be drawn. cAbsolute risk estimates for withdrawals not provided because of inconsistent results from randomized controlled trials and observational data.